Home > Publications database > Selective elimination of immunosuppressive T cells in patients with multiple myeloma. > print

001     167550
005     20240917134515.0
024 7 _ |a 10.1038/s41375-021-01172-x
|2 doi
024 7 _ |a pmid:33597728
|2 pmid
024 7 _ |a 0887-6924
|2 ISSN
024 7 _ |a 1476-5551
|2 ISSN
024 7 _ |a altmetric:100396477
|2 altmetric
037 _ _ |a DKFZ-2021-00415
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Awwad, Mohamed H S
|b 0
245 _ _ |a Selective elimination of immunosuppressive T cells in patients with multiple myeloma.
260 _ _ |a London
|c 2021
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1726573490_21166
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2021 Sep;35(9):2602-2615
520 _ _ |a Elimination of suppressive T cells may enable and enhance cancer immunotherapy. Here, we demonstrate that the cell membrane protein SLAMF7 was highly expressed on immunosuppressive CD8+CD28-CD57+ Tregs in multiple myeloma (MM). SLAMF7 expression associated with T cell exhaustion surface markers and exhaustion-related transcription factor signatures. T cells from patients with a high frequency of SLAMF7+CD8+ T cells exhibited decreased immunoreactivity towards the MART-1aa26-35*A27L antigen. A monoclonal anti-SLAMF7 antibody (elotuzumab) specifically depleted SLAMF7+CD8+ T cells in vitro and in vivo via macrophage-mediated antibody-dependent cellular phagocytosis (ADCP). Anti-SLAMF7 treatment of MM patients depleted suppressive T cells in peripheral blood. These data highlight SLAMF7 as a marker for suppressive CD8+ Treg and suggest that anti-SLAMF7 antibodies can be used to boost anti-tumoral immune responses in cancer patients.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Mahmoud, Abdelrahman
|b 1
700 1 _ |a Bruns, Heiko
|b 2
700 1 _ |a Echchannaoui, Hakim
|0 P:(DE-He78)d32743f5aa1b7577cded5ce1d6c153bf
|b 3
|u dkfz
700 1 _ |a Kriegsmann, Katharina
|b 4
700 1 _ |a Lutz, Raphael
|b 5
700 1 _ |a Raab, Marc-Steffen
|0 P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3
|b 6
|u dkfz
700 1 _ |a Bertsch, Uta
|b 7
700 1 _ |a Munder, Markus
|b 8
700 1 _ |a Jauch, Anna
|b 9
700 1 _ |a Weisel, Katja
|b 10
700 1 _ |a Maier, Bettina
|b 11
700 1 _ |a Weinhold, Niels
|b 12
700 1 _ |a Salwender, Hans Jürgen
|b 13
700 1 _ |a Eckstein, Volker
|b 14
700 1 _ |a Hänel, Mathias
|b 15
700 1 _ |a Fenk, Roland
|b 16
700 1 _ |a Dürig, Jan
|b 17
700 1 _ |a Brors, Benedikt
|0 P:(DE-He78)fc949170377b58098e46141d95c72661
|b 18
|u dkfz
700 1 _ |a Benner, Axel
|0 P:(DE-He78)e15dfa1260625c69d6690a197392a994
|b 19
|u dkfz
700 1 _ |a Müller-Tidow, Carsten
|0 0000-0002-7166-5232
|b 20
700 1 _ |a Goldschmidt, Hartmut
|b 21
700 1 _ |a Hundemer, Michael
|0 0000-0002-5596-2405
|b 22
773 _ _ |a 10.1038/s41375-021-01172-x
|0 PERI:(DE-600)2008023-2
|n 9
|p 2602-2615
|t Leukemia
|v 35
|y 2021
|x 1476-5551
909 C O |p VDB
|o oai:inrepo02.dkfz.de:167550
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)d32743f5aa1b7577cded5ce1d6c153bf
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)fc949170377b58098e46141d95c72661
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)e15dfa1260625c69d6690a197392a994
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-319H
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Addenda
|x 0
914 1 _ |y 2021
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b LEUKEMIA : 2018
|d 2020-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2020-09-04
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2020-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2020-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-09-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-09-04
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b LEUKEMIA : 2018
|d 2020-09-04
920 1 _ |0 I:(DE-He78)FM01-20160331
|k FM01
|l DKTK Koordinierungsstelle Frankfurt
|x 0
920 1 _ |0 I:(DE-He78)A360-20160331
|k A360
|l KKE Mol. Hämatologie/Onkologie
|x 1
920 1 _ |0 I:(DE-He78)B330-20160331
|k B330
|l Angewandte Bioinformatik
|x 2
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)FM01-20160331
980 _ _ |a I:(DE-He78)A360-20160331
980 _ _ |a I:(DE-He78)B330-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21